While the company continued to grow well in the domestic arena, the sales growth in most other geographies remained subdued. Operating profits improved 6% y-o-y, operating margins at 30% helped by lower operating costs were better than 28% in the year-ago quarter. As reported profit growth impressed, the expectations of a rebound in sales growth are driving the stock prices. The company has a strong product range for the domestic market and domestic growth of 10% beating India pharma market growth of 5% during Q4 encourages. Though the near-term impact of covid led disruption remains unclear, nevertheless, domestic growth momentum is likely to remain strong, feel analysts.

Source: Mint May 19, 2021 05:50 UTC